Neuropsychiatric Disorders

Advancing Neuropsychiatric Drug Discovery

At Ulysses Neuroscience, we combine over two decades of neuropharmacology expertise with state-of-the-art translational platforms to accelerate therapeutic development for neuropsychiatric disorders. Our validated preclinical models capture the core behavioural, molecular, and electrophysiological features of mood and psychotic disorders, enabling robust efficacy testing and mechanistic investigation. From inflammation-driven depression to treatment-resistant phenotypes and stress-induced pathology, our integrated approach bridges preclinical findings with clinical endpoints—delivering data that de-risks your pipeline and supports regulatory submissions.